Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398776 | 0.92 | SLC18A3 (0.35) | SIGMAR1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23085113 | 0.92 | SLC18A3 (0.35) | SIGMAR1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25703421 | 0.83 | SIGMAR1 (0.37) | SIGMAR1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27403757 | 0.82 | MEN1 (0.40) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL25703442 | 0.81 | ATM (0.34) | SIGMAR1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22593578 | 0.79 | CA2 (0.41) | SIGMAR1SLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL22815239 | 0.78 | SLC18A3 (0.38) | SIGMAR1SLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL27398620 | 0.78 | SLC18A3 (0.38) | SIGMAR1SLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL30329419 | 0.75 | CA2 (0.40) | SIGMAR1SLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL25162267 | 0.75 | SLC18A3 (0.35) | SIGMAR1SLC18A3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192853-A1 | CD8 BINDING AGENTS AND USES THEREOF | GENENTECH, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192853-A1 | CD8 BINDING AGENTS AND USES THEREOF | CD81, CD4, HAVCR2 | LTA4H 1710/4885SIGMAR1 3502/4885SLC18A3 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.